Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 11.1 mg (equivalent: esomeprazole, qty 10 mg) - granules, enteric-coated - excipient ingredients: crospovidone; xanthan gum; polysorbate 80; hyprolose; triethyl citrate; hypromellose; iron oxide yellow; magnesium stearate; citric acid; purified talc; glucose; glyceryl monostearate; methacrylic acid copolymer; maize starch; sucrose; hydrolysed maize starch - nexium is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with nexium iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 44.5 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: iron oxide red; microcrystalline cellulose; polysorbate 80; triethyl citrate; synthetic paraffin; titanium dioxide; crospovidone; hypromellose; purified talc; glyceryl monostearate; methacrylic acid copolymer; magnesium stearate; hyprolose; sodium stearylfumarate; macrogol 6000; maize starch; sucrose - nexium is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with nexium iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified talc; glyceryl monostearate; iron oxide yellow; hypromellose; microcrystalline cellulose; methacrylic acid copolymer; synthetic paraffin; iron oxide red; triethyl citrate; macrogol 6000; polysorbate 80; crospovidone; titanium dioxide; magnesium stearate; hyprolose; sodium stearylfumarate; maize starch; sucrose - nexium is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with nexium iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Israel - English - Ministry of Health

taro international ltd, israel - esomeprazole - tablets - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 20 mg tablets are indicated in adolescents from the age of 12 years forgastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophgeal reflux disease (gerd)in combination with antibiotics in treatment of duodenal ulcer caused by helicobactor pylori

Israel - English - Ministry of Health

astrazeneca (israel) ltd - esomeprazole - tablets - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 20 mg tablets are indicated in adolescents from the age of 12 years forgastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagi

Israel - English - Ministry of Health

taro international ltd, israel - esomeprazole - tablets - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 40 mg tablets are indicated in adolescents from the age of 12 years for;gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis

Israel - English - Ministry of Health

astrazeneca (israel) ltd - esomeprazole - tablets - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 40 mg tablets are indicated in adolescents from the age of 12 years for;gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis

European Union - English - EMA (European Medicines Agency)

glaxosmithkline dungarvan limited - esomeprazole - gastroesophageal reflux - proton pump inhibitors - nexium control is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole sodium, quantity: 42.5 mg (equivalent: esomeprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; disodium edetate - nexium iv: the short-term management of gastro-oesophageal reflux disease (gord) in patients with oesophagitis and/or severe symptoms of reflux as an alternative when oral therapy is inappropriate. prevention of rebleeding in patients following therapeutic endoscopy for acute, bleeding gastric or duodenal ulcers. short-term management in patients requiring continued non-steroidal anti-inflammatory drug (nsaid) therapy when oral therapy is inappropriate: - healing of gastric ulcers associated with nsaid therapy; - prevention of gastric and duodenal ulcers associated with nsaid therapy, in patients at risk. nexium iv should be replaced with oral therapy as soon as practicable.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - esomeprazole - tablets - esomeprazole 20 mg - esomeprazole - nexium tablets are indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagitis to prevent relapse- symptomatic treatment of gastroesophageal reflux disease (gerd)in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and:- healing of helicobacter pylori associated duodenal ulcer and- prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers.patients requiring nsaid therapy- healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.nexium 20 mg tablets are indicated in adolescents from the age of 12 years forgastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis- long-term management of patients with healed esophagi